18.44USD-4.33%Mkt Cap: 613.84M USDP/E: —Last update: 2026-06-01
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL S…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap613.84M USD
Enterprise Value742.48M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-39.87M USD
Revenue/Share—
Last Price18.44 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees65
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.14
PEG—
EV/EBITDA-18.18
EV/Revenue—
P/S—
P/B2.57
EPS (TTM)-1.34
EPS (Forward)-2.70
52W Range
18.370% of range32.44
52W High32.44 USD
52W Low18.37 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE40.34%
ROA-34.41%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-32.70M USD
CapEx (TTM)789.00K USD
FCF Margin—
FCF Yield-3.62%
Net Debt-105.85M USD
Net Debt/EBITDA2.59
Balance Sheet
Debt/Equity-0.02
Current Ratio12.67
Quick Ratio12.57
Book Value/Sh7.481 USD
Cash/Share3.214 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)45.00 USD
Target Range37.00 USD – 62.00 USD
# Analysts5
Ownership
Shares Out.33.43M
Float6.48M
Insiders4.28%
Institutions92.28%
Short Interest
Short Ratio15.1d
Short % Float7.74%
Short % Out.2.57%
Shares Short858.55K
Short (prev mo.)1.04M
Technical
SMA 5023.52 (-21.6%)
SMA 20024.94 (-26.1%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)56.99K
Avg Vol (10d)55.70K
Technical Indicators
RSI (14)30.8
MACD-1.1006
MACD Signal-0.7300
MACD Hist.-0.3706
BB Upper26.41 USD
BB Middle22.70 USD
BB Lower18.99 USD
BB Width32.70%
ATR (14)1.581 USD
Vol Ratio (20d)0.48x